Diclofenac sodium
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Blunt Soft Tissue Injuries/Contusions
Conditions
Acute Blunt Soft Tissue Injuries/Contusions
Trial Timeline
Jan 1, 2011 → Jul 1, 2011
NCT ID
NCT01272947About Diclofenac sodium
Diclofenac sodium is a phase 3 stage product being developed by Novartis for Acute Blunt Soft Tissue Injuries/Contusions. The current trial status is completed. This product is registered under clinical trial identifier NCT01272947. Target conditions include Acute Blunt Soft Tissue Injuries/Contusions.
What happened to similar drugs?
20 of 20 similar drugs in Acute Blunt Soft Tissue Injuries/Contusions were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01272947 | Phase 3 | Completed |
| NCT01272934 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Blunt Soft Tissue Injuries/Contusions